Investigational Drug Information for Parsaclisib
✉ Email this page to a colleague
What is the drug development status for Parsaclisib?
Parsaclisib is an investigational drug.
There have been 32 clinical trials for Parsaclisib.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 24th 2021.
The most common disease conditions in clinical trials are Lymphoma, Lymphoma, Follicular, and Primary Myelofibrosis. The leading clinical trial sponsors are Incyte Corporation, Incyte Biosciences Japan GK, and Innovent Biologics (Suzhou) Co. Ltd.
There are ten US patents protecting this investigational drug and two hundred and eighty-two international patents.
Summary for Parsaclisib
| US Patents | 10 |
| International Patents | 282 |
| US Patent Applications | 61 |
| WIPO Patent Applications | 38 |
| Japanese Patent Applications | 8 |
| Clinical Trial Progress | Phase 2 (2021-05-24) |
| Vendors | 32 |
Recent Clinical Trials for Parsaclisib
| Title | Sponsor | Phase |
|---|---|---|
| Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL | Fudan University | Phase 1/Phase 2 |
| To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) | Incyte Corporation | Phase 3 |
Clinical Trial Summary for Parsaclisib
Top disease conditions for Parsaclisib
Top clinical trial sponsors for Parsaclisib
US Patents for Parsaclisib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Parsaclisib | ⤷ Sign Up | Bicyclic fused pyrimidine compounds as TAM inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Sign Up |
| Parsaclisib | ⤷ Sign Up | Pyrrolopyrimidine derivatives as TAM inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Sign Up |
| Parsaclisib | ⤷ Sign Up | Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Sign Up |
| Parsaclisib | ⤷ Sign Up | Heterocyclic compounds as PI3K-.gamma. inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Sign Up |
| Parsaclisib | ⤷ Sign Up | Salts and processes of preparing a PI3K inhibitor | Incyte Corporation (Wilmington, DE) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Parsaclisib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Parsaclisib | World Intellectual Property Organization (WIPO) | WO2017027717 | 2035-08-12 | ⤷ Sign Up |
| Parsaclisib | World Intellectual Property Organization (WIPO) | WO2017035366 | 2035-08-26 | ⤷ Sign Up |
| Parsaclisib | Australia | AU2015244044 | 2034-04-08 | ⤷ Sign Up |
| Parsaclisib | Australia | AU2020213313 | 2034-04-08 | ⤷ Sign Up |
| Parsaclisib | Australia | AU2022206693 | 2034-04-08 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
